Table 2.
Selected clinical studies with pending data
| Generic name (sponsor) | Modality | Delivery route | Primary integrin target | Indication | ClinicalTrials.gov identifiers | Study statusa |
|---|---|---|---|---|---|---|
| IDL-2965 (Indalo Therapeutics) | Small molecule | Oral | αvβ1, αvβ3, αvβ6 | IPF186, NASH187 | NCT03949530 | Terminated |
| PLN-74809 (Pliant Therapeutics) 15 | Small molecule | Oral | αvβ6, αvβ1 | IPF, primary sclerosing cholangitis | NCT04072315, NCT04396756, NCT04480840 | Recruiting |
| PLN-1474 (Pliant Therapeutics) | Small molecule | Oral | αvβ1 | End-stage liver fibrosis in NASH | Not available | Recruiting |
| PN-943 (Protagonist Therapeutics) | Peptide | Oral | α4β7 | Ulcerative colitis | NCT04504383 | Recruiting |
| CAR-T therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Cell-based therapy | i.v. | β7 | Relapsed/refractory multiple myeloma | NCT03778346 | Recruiting |
| 7HP349 (7 Hills Pharma) | Small molecule | Oral | αLβ2, α4β1 | Solid tumours | NCT04508179 | Recruiting |
| MORF-057 (Morphic Therapeutics) | Small molecule | Oral | α4β7 | Healthy volunteers | NCT04580745 | Active, not recruiting |
| JSM-6427 (Jerini AG & Shire Pharmaceuticals, now Takeda Pharma) 3 | Small molecule | Parenteral | α5β1 (also binds αvβ6/8) | Age-related macular degeneration | NCT00536016 | Completed |
| OS2966 (OncoSynergy) | mAb | Intratumoural infusion | β1 | Glioma | NCT04608812 | Recruiting |
| AXT-107 (AsclepiX Therapeutics) | Peptide | Intravitreal injection | αvβ3, α5β1 | DME, nAMD | NCT04697758, NCT04746963 | Recruiting |
Emerging integrin-targeting therapies that are currently in clinical trials, or that have been in clinical trials but have not published any findings. This table details novel potential drugs intended as disease therapy, rather than those with potential diagnostic or prognostic value. Studies that have a clinical trials identifiers (NCT numbers) are indicated, together with the associated study status according to the latest data from www.clinicaltrials.gov. Numbers in bold refer to the molecule structures shown in Figs 2,3. DME, diabetic macular oedema; IPF, idiopathic pulmonary fibrosis; i.v., intravenous; mAb, monoclonal antibody; nAMD, neovascular age-related macular degeneration; NASH, nonalcoholic steatohepatitis. aStudy status information correct as of May 2021.